Regeneron Pharmaceuticals (REGN) Notes Payables (2014 - 2020)
Regeneron Pharmaceuticals' quarterly Notes Payables came in at $1.5 billion in Q2 2020, up 93650.0% quarter-over-quarter from $1.6 million in Q4 2015.
Regeneron Pharmaceuticals has reported Notes Payables for 3 years, with the latest figure at $1.5 billion in Q2 2020.
- For the quarter ending Q2 2020, Notes Payables changed N/A year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2020 stood at $1.5 billion (changed N/A YoY), and the FY2015 full-year result was $1.6 million, down 78.67% from the prior year.
- Notes Payables for Q2 2020 stood at $1.5 billion, up from $1.6 million in the prior quarter.
- The five-year high for Notes Payables was $1.5 billion in Q2 2020, with the low at $1.5 billion in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 1.50 Bn |
| Dec 31, 2015 | 1.60 Mn |
| Dec 31, 2014 | 7.50 Mn |